Cargando…

Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers

(i) Background: ChAdOx1 nCoV-19 (Covishield(®)) vaccine is widely used in India. We studied the Covishield(®) induced antibody response and its durability among health care workers (HCWs) (ii) Method: HCWs received two doses (0.5 mL) four weeks apart. Blood specimens, collected before each dose, day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Alka, Goel, Amit, Katiyar, Harshita, Tiwari, Prachi, , Mayank, Sana, Asari, Khetan, Dheeraj, Bhadauria, Dharmendra Singh, Raja, Ajay, Khokher, Neelam, , Shalimar, Singh, Ratendra Kumar, Aggarwal, Amita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863895/ https://www.ncbi.nlm.nih.gov/pubmed/36679930 http://dx.doi.org/10.3390/vaccines11010084

Ejemplares similares

Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022)

Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
por: Bhadauria, Dharmendra S., et al.
Publicado: (2022)

Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022)

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022)

Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
por: Devi, Leimapokpam Sumitra, et al.
Publicado: (2022)

Post Covishield (ChAdOx1 nCoV-19) Vaccination: New Onset Focal Segmental Glomerulosclerosis Resistant to Steroid and Calcineurin Inhibitor
por: Jha, Vijoy Kumar, et al.
Publicado: (2022)

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center
por: Prasad, Narayan, et al.
Publicado: (2022)

Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications
por: Sahoo, Soumya Swaroop, et al.
Publicado: (2022)

Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study
por: Velhal, Gajanan D., et al.
Publicado: (2022)

Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine
por: Rizvi, Imran, et al.
Publicado: (2022)

COVID‐19 vaccine (ChAdOx1 nCoV‐19 Corona virus vaccine (Recombinant) – COVISHIELD related MS relapse
por: Mathew, Thomas, et al.
Publicado: (2021)

Parsonage-Turner Syndrome Following Covishield (AstraZeneca ChAdOx1 nCoV-19) Vaccination: A Case Report
por: Lakkireddy, Maheshwar, et al.
Publicado: (2022)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
por: Natung, Tanie, et al.
Publicado: (2023)

Short Research Communication Anti-Spike Antibody Response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients
por: Chopra, Madhu, et al.
Publicado: (2022)

Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study
por: Kamal, Deep, et al.
Publicado: (2021)

Prevalence of Covishield COVID-19 Vaccine (ChAdOx1 nCoV-19) Adverse Effects among Health Care Workers in Sri Lanka
por: Manilgama, S.R., et al.
Publicado: (2022)

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield(TM)) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
por: Murali, Sharan, et al.
Publicado: (2022)

Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study
por: Meher, Trupti, et al.
Publicado: (2023)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir
por: Katiyar, Harshita, et al.
Publicado: (2023)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

A case of acute endothelial corneal transplant rejection following immunization with ChAdOx1 nCoV-19 coronavirus vaccine
por: Nahata, Harshita, et al.
Publicado: (2022)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
por: Konu, Yao Rodion, et al.
Publicado: (2021)

Covishield™ (ChAdOx1 nCoV-19) Vaccine-Induced Systemic Drug-Related Intertriginous and Flexural Exanthema in a Young Girl: A Case Report and Literature Review
por: Sandhu, Jaspriya, et al.
Publicado: (2022)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study
por: Subedi, Prativa, et al.
Publicado: (2021)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e1k6k6cps267seh9pj0uk1p7g1